Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 12, 2014, Pages 1996-2005

  Masaki, Naohiko ^a   Sugiyama, Masaya ^a   Shimada, Noritomo ^b   Tanaka, Yasuhito ^c   Nakamuta, Makoto ^d   Izumi, Namiki ^e   Watanabe, Sumio ^f   Tsubota, Akihito ^g   Komatsu, Masafumi ^h   Masaki, Tsutomu ⁱ   Enomoto, Nobuyuki ^j   Yoneda, Masashi ^k   Murata, Kazumoto ^a   Ito, Kiyoaki ^a,k   Koike, Kazuhiko ^l   Mizokami, Masashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Shinmatsudo Central General Hospital   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^e MUSASHINO RED CROSS HOSPITAL   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Akita City Hosp   (Japan)

ⁱ KAGAWA UNIVERSITY   (Japan)

^j UNIVERSITY OF YAMANASHI   (Japan)

^k AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

(TA) dinucleotide repeat; Chronic hepatitis C; IL28B; Response guided therapy

Indexed keywords

AMINO ACID; HOST FACTOR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DINUCLEOTIDE REPEAT; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS CORE; VIRUS LOAD; AGED; FORECASTING; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; VIROLOGY;

AGED; ANTIVIRAL AGENTS; FEMALE; FORECASTING; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84929030416     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12646     Document Type: Article

References (33)

1. World Health Organization. WHO Fact sheet N°164, Updated April 2014. Hepatitis C. Cited 19 June 2014. Available from URL: http://www.who.int/mediacentre/factsheets/fs164/en/index.html
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1443.
3. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
4. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
5. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
6. McHutchison JG, Manns MP, Muir AJ etal. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 1292-1303.
7. Chayama K, Takahashi S, Toyota J etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748.
8. Gane EJ, Stedman CA, Hyland RH etal. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013; 368: 34-44.
9. Poordad F, Lawitz E, Kowdley KV etal. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 2013; 368: 45-53.
10. Guedj H, Guedj J, Negro F etal. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J. Viral Hepat. 2012; 19: 488-496.
11. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012; 56: 464-473.
12. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380.
13. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 77-81.
14. Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol. Clin. North Am. 2004; 33: 11-24.
15. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
16. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
17. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
18. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
19. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
20. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS ONE 2011; 6: e26620.
21. Tsukiyama-Kohara K, Yamaguchi K, Maki N etal. Antigenicities of group I and II hepatitis C virus polypeptides-molecular basis of diagnosis. Virology 1993; 192: 430-437.
22. Ohno T, Mizokami M, Wu RR etal. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J. Clin. Microbiol. 1997; 35: 201-207.
23. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
24. Izumi N, Nishiguchi S, Hino K etal. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol. Res. 2010; 40: 347-368.
25. Ito K, Higami K, Masaki N etal. The rs8099917 polymorphism, determined by a suitable genotyping method, is a better predictor for response to pegylated interferon-alpha/ribavirin therapy in Japanese patients than other SNPs associated with IL28B. J. Clin. Microbiol. 2011; 49: 1853-1860.
26. Lyamichev VI, Kaiser MW, Lyamicheva NE etal. Experimental and theoretical analysis of the invasive signal amplification reaction. Biochemistry 2000; 39: 9523-9532.
27. Hall JG, Eis PS, Law SM etal. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 8272-8277.
28. Sterling RK, Lissen E, Clumeck N etal. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
29. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-264.
30. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580-593.
31. Everhart JE, Wright EC. Association of γ-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology 2013; 57: 1725-1733.
32. Saito H, Ito K, Sugiyama M etal. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. Hepatol. Res. 2012; 42: 958-965.
33. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.